Bojiyuan raises tens of millions of yuan to push eczema drug into Phase IIb
What's the deal? Bojiyuan (Shanghai) BiopharmaceuticalDealroom has a profile for this one. Try Dealroom → has closed a Series A extension round worth tens of millions of yuan, announced in October 2026. Investors include Qinzhi Capital, Fuhui Venture Capital, and individual backers, with existing shareholders adding to their stakes.
What's the endgame? The money will mainly fund Phase IIb clinical development of BGT-010, the company's lead program, a GPR84 antagonist targeting atopic dermatitis. Bojiyuan also plans to expand into new indications and advance several preclinical candidates.
Why now? The round lands as investment in Chinese innovative drugs recovers, with funding and deal activity picking up in recent years. But capital is now more selective, favouring assets with clear clinical validation milestones over early-stage promises.
What could go wrong? The key test is whether Phase II data can validate the drug, not the size of the raise. Bojiyuan's claims about its efficacy potential remain management statements, not proven advantages, and the round's undisclosed amount makes its scale hard to gauge.
The signal: Continued backing from existing investors suggests confidence in the pipeline, but the market's new discipline means Bojiyuan will be judged on trial results rather than headlines.
Read more: sohu.com
Image credit: Generated with Gemini
